PURPOSE: The aim of this study was to assess the feasibility and effectiveness of magnetic resonance (MRI)-guided focused ultrasound (MRIgFUS) ablation for uterine fibroids and to identify the candidates for this treatment. MATERIALS AND METHODS: A total of 48 patients with a symptomatic uterine fibroid underwent MRIgFUS. The percent ablation volume was calculated, and the patients' characteristics and the MR imaging features of the fibroids that might predict the effect of this treatment were assessed. Changes in the symptoms related to the uterine fibroid were assessed at 6 and 12 months. RESULTS: The planned target zone were successfully treated in 32 patients with bulk-related and menstrual symptoms but unsuccessfully treated in the remaining 16 patients. These 16 patients were obese or their uterine fibroid showed heterogeneous high signal intensity on T2-weighted images. The 32 successfully treated patients were followed up for 6 months. At the 6-month follow-up, bulk-related and menstrual symptoms were diminished in 60% and 51% of patients, respectively. Among them, 17 patients were followed up for 12 months, and 9 of them who showed alleviation of bulk-related symptoms at 6 months had further improvement. The mean percent ablation volume of those nine patients was 51%. In 5 (33%) of the 15 patients with alleviation of menstrual symptoms at 6 months, the symptoms became worse at 12 months. There was a significant difference in the mean percent ablation volume between patients with alleviation of menstrual symptoms and those without (54% vs. 37%; P = 0.03). CONCLUSION: MRIgFUS ablation is a safe, effective treatment for nonobese patients with symptomatic fibroids that show low signal intensity on T2-weighted images. Ablation of more than 50% of the fibroid volume may be needed with a short-term follow-up.
PURPOSE: The aim of this study was to assess the feasibility and effectiveness of magnetic resonance (MRI)-guided focused ultrasound (MRIgFUS) ablation for uterine fibroids and to identify the candidates for this treatment. MATERIALS AND METHODS: A total of 48 patients with a symptomatic uterine fibroid underwent MRIgFUS. The percent ablation volume was calculated, and the patients' characteristics and the MR imaging features of the fibroids that might predict the effect of this treatment were assessed. Changes in the symptoms related to the uterine fibroid were assessed at 6 and 12 months. RESULTS: The planned target zone were successfully treated in 32 patients with bulk-related and menstrual symptoms but unsuccessfully treated in the remaining 16 patients. These 16 patients were obese or their uterine fibroid showed heterogeneous high signal intensity on T2-weighted images. The 32 successfully treated patients were followed up for 6 months. At the 6-month follow-up, bulk-related and menstrual symptoms were diminished in 60% and 51% of patients, respectively. Among them, 17 patients were followed up for 12 months, and 9 of them who showed alleviation of bulk-related symptoms at 6 months had further improvement. The mean percent ablation volume of those nine patients was 51%. In 5 (33%) of the 15 patients with alleviation of menstrual symptoms at 6 months, the symptoms became worse at 12 months. There was a significant difference in the mean percent ablation volume between patients with alleviation of menstrual symptoms and those without (54% vs. 37%; P = 0.03). CONCLUSION:MRIgFUS ablation is a safe, effective treatment for nonobese patients with symptomatic fibroids that show low signal intensity on T2-weighted images. Ablation of more than 50% of the fibroid volume may be needed with a short-term follow-up.
Authors: J H Ravina; D Herbreteau; N Ciraru-Vigneron; J M Bouret; E Houdart; A Aymard; J J Merland Journal: Lancet Date: 1995-09-09 Impact factor: 79.321
Authors: H Ueda; K Togashi; I Konishi; M L Kataoka; T Koyama; T Fujiwara; H Kobayashi; S Fujii; J Konishi Journal: Radiographics Date: 1999-10 Impact factor: 5.333
Authors: Elizabeth A Stewart; Wladyslaw M W Gedroyc; Clare M C Tempany; Bradley J Quade; Yael Inbar; Tilman Ehrenstein; Asher Shushan; Jonathan T Hindley; Robert D Goldin; Matthias David; Miri Sklair; Jaron Rabinovici Journal: Am J Obstet Gynecol Date: 2003-07 Impact factor: 8.661
Authors: Fiona M Fennessy; Clare M Tempany; Nathan J McDannold; Minna J So; Gina Hesley; Bobbie Gostout; Hyun S Kim; George A Holland; Dennis A Sarti; Kullervo Hynynen; Ferenc A Jolesz; Elizabeth A Stewart Journal: Radiology Date: 2007-04-19 Impact factor: 11.105
Authors: Bryan D Cowan; Patrick E Sewell; Jeffery C Howard; Richard M Arriola; Lynda G Robinette Journal: Am J Obstet Gynecol Date: 2002-06 Impact factor: 8.661
Authors: Xin Chen; Petr Novák; Donald G Benson; Jessica S Webber; Leah Hennings; Gal Shafirstein; Peter M Corry; Robert J Griffin; Eduardo G Moros Journal: Med Phys Date: 2011-04 Impact factor: 4.071
Authors: Marlijne E Ikink; Marianne J Voogt; Helena M Verkooijen; Paul N M Lohle; Karlijn J Schweitzer; Arie Franx; Willem P Th M Mali; Lambertus W Bartels; Maurice A A J van den Bosch Journal: Eur Radiol Date: 2013-06-21 Impact factor: 5.315
Authors: M Xia; Z Jing; H Zhi-Yu; C Jian-Ming; Z Hong-Yu; X Rui-Fang; Y Yu; H Yan-Li; D Bao-Wei Journal: Br J Radiol Date: 2014-06-20 Impact factor: 3.039